Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06924970 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Eligibility criteria expanded, about 11 words Site details revised at 2 of 20 sites Show 1 more changeShow less
    • Site details revised at 2 of 20 sites
  2. Trial sites reduced: 30 → 20 locations Primary completion date changed from estimate of May 2026 to May 12, 2026v15 Show 1 more changeShow less
    • Primary completion date changed from estimate of May 2026 to May 12, 2026
  3. Re-verified, no change to tracked fieldsv14
  4. Trial status changed: Recruiting → Active, Not Recruiting Enrollment target: estimated 56 to confirmed 59 · Study sites: 32 to 30v13 Show 2 more changesShow less
    • Enrollment target: estimated 56 to confirmed 59
    • Study sites: 32 to 30
  5. Re-verified, no change to tracked fieldsv12
Show 10 earlier versionsHide 10 earlier versions
  1. Study sites: 31 to 32v11
  2. Study sites: 29 to 31v10
  3. Study sites: 24 to 29v9
  4. Study sites: 15 to 24v8
  5. Study sites: 8 to 15v7
  6. Study sites: 3 to 8v6
  7. Study sites: 2 to 3v5
  8. Re-verified, no change to tracked fieldsv4
  9. Study sites: 1 to 2v3
  10. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of May 6, 2025 to May 1, 2025v2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of May 6, 2025 to May 1, 2025
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main purpose of this study is to compare the effect of tebapivat versus placebo on anemia and to detect a dose-response for hemoglobin (Hb) response in participants with SCD.
Trial Details
NCT Number NCT06924970
Lead Sponsor Agios Pharmaceuticals, Inc.
Conditions Sickle Cell Disease
Enrollment 59 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov